Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

A Phase III, Single-arm Study to Evaluate the Efficacy and Safety of ONCOFID-P-B (Paclitaxel-hyaluronic Acid Conjugate) Administered Intravesically to Patients With BCG-unresponsive Carcinoma in Situ of the Bladder With or Without Ta-T1 Papillary Disease (Orion-BC)

This is a phase III, single-arm, multicenter, international study to assess the efficacy and safety of ONCOFID-P-B following intravesical instillation in adult patients with histologically and cytologically confirmed CIS, with or without concomitant Ta-T1, who are unresponsive to BCG therapy and unwilling or unfit to undergo radical cystectomy.

After providing written informed consent (in presence of an Independent Witness, if applicable), patients will receive an induction therapy consisting of 12 weekly intravesical instillations of ONCOFID-P-B (induction phase). Patients with residual CIS at the end of induction treatment are eligible to enter a re-induction course of therapy (reinduction phase). Patients with stable disease by Investigator assessment defined as neither increased or decreased in extent or severity compared to baseline, are not eligible for re-induction therapy. Patients who achieve a complete resonde (CR) at the end of the induction or re-induction phase enter in the maintenance phase and receive monthly intravesical instillations of ONCOFID-P-B for an additional 12 monsthe or untile recurrence of CIS/HG Ta-T1 or progression to MIBC or extravesical disease. Patients who do not achieve a CR at the end of induction or re-induction phase, will discontinue investigational treatement and are followed up until month 48 from induction or re-induction start, or until a new antitumor therapy is initiated, wichever occurs first.

Tumor response is evaluated by cystoscopy, cytology and biopsy at the end of the induction and re-induction phases and at Safety Follow Up Visit (SFUV). During the maintenance/follow-up period, tumorresponse is evaluated by cystoscopy and cytology every 3 months for up to 24 months from induction or re-induction start, and then every 6 months for an additional 2 years (long-term follow-up). Tumor biopsies are performed in case of of positive cystoscopy and/or cytology. Random biopsies are to be performed at 6, 12 and 18 months after the end of the induction or re-induction phase in responding patients (i.e. at 9, 15 and 21 months after induction or re-induction start.

Study Overview

• Status: Recruiting
• Conditions: Bladder Carcinoma in Situ (CIS)
• Intervention / Treatment: Drug: ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)

• Study Type: Interventional
• Enrollment (Estimated): 112
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Nicola Giordan; Phone Number: +390498232512; Email: ngiordan@fidiapharma.it

Study Locations

• France
  • Bordeaux, France, 33000
    • Recruiting
    • CHU Bordeaux -Hopital Pellegrin
    • Contact: Gregoire Robert, MD
    • Principal Investigator: Gregoire Robert, MD
  • Clermont-Ferrand, France, 63000
    • Recruiting
    • CHU de Clermont-Ferrand - Hopital Gabriel Montpied
    • Contact: Laurent Guy, MD
    • Principal Investigator: Laurent Guy, MD
  • Lille, France, 59000
    • Recruiting
    • CHU de LILLE - Hopital Claude Huriez
    • Contact: Gautier Marcq, MD
    • Principal Investigator: Gautier Marcq, MD
  • Marseille, France, 13009
    • Recruiting
    • Institute Paoli-Calmettes
    • Contact: Geraldine Pignot, MD
    • Principal Investigator: Geraldine Pignot, MD
  • Paris, France, 75018
    • Recruiting
    • AP-HP Hopital Bichat-Claude Bernard
    • Contact: Evanguelos Xylinas, MD
    • Principal Investigator: Evanguelos Xylinas, MD
  • Paris, France, 75020
    • Terminated
    • AP-HP Hopital Tenon
  • Poitiers, France, 90577
    • Recruiting
    • Centre Hospitalier Universitaire Poitiers
    • Contact: Simon Bernardeu, MD
    • Principal Investigator: Simon Bernardeu, MD
• Italy
  • Bergamo, Italy, 24125
    • Recruiting
    • Humanitas Gavazzeni
    • Contact: Angelo Porreca, MD
    • Principal Investigator: Angelo Porreca, MD
  • Bologna, Italy, 40138
    • Recruiting
    • IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola
    • Contact: Francesco Chessa, MD
    • Principal Investigator: Francesco Chessa, MD
  • Castelfranco Veneto, Italy, 31033
    • Recruiting
    • Istituto Oncologico Veneto-I.R.C.C.S.-Ospedale San Giacomo
    • Principal Investigator: Antonio Amodeo, MD
    • Contact: Antonio Amodeo, MD
  • Florence, Italy, 50134
    • Recruiting
    • Azienda Ospedaliero-Universitaria Careggi
    • Principal Investigator: Mauro Gacci, MD
    • Contact: Mauro Gacci, MD
  • Lecce, Italy, 73100
    • Recruiting
    • ASL Lecce- Ospedale Vito Fazzi
    • Contact: Vincenzo Pagliarulo, MD
    • Principal Investigator: Vincenzo Pagliarulo, MD
  • Milan, Italy, 20133
    • Recruiting
    • Fondazione IRCCS Istituto Nazionale dei Tumori
    • Contact: Alberto Macchi, MD
    • Principal Investigator: Alberto Macchi, MD
  • Milan, Italy, 20089
    • Recruiting
    • Istituto Clinico Humanitas
    • Contact: Rodolfo Hurle, MD
    • Principal Investigator: Rodolfo Hurle, MD
  • Milan, Italy, 20132
    • Recruiting
    • IRCSS Ospedale San Raffaele
    • Contact: Marco Moschini, MD
    • Principal Investigator: Marco Moschini, MD
  • Naples, Italy, 80131
    • Recruiting
    • Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
    • Contact: Rosa Tambaro, MD
    • Principal Investigator: Rosa Tambaro, MD
  • Roma, Italy, 00128
    • Recruiting
    • IFO-Istituto Nazionale dei Tumori Regina Elena
    • Principal Investigator: Giuseppe Simone, MD
    • Contact: Giuseppe Simone; Phone Number: MD
  • Torino, Italy, 10126
    • Recruiting
    • AOU Città della Salute e della Scienza di Torino-Ospedale le Molinette
    • Contact: Francesco Soria, MD
    • Principal Investigator: Francesco Soria, MD
  • Verona, Italy, 37126
    • Recruiting
    • Azienda Ospedaliera Universitaria Integrata Verona-Ospedale Borgo Trento
    • Contact: Alessandro Antonelli, MD
    • Principal Investigator: Alessandro Antonelli, MD
• Poland
  • Lublin, Poland, 20-090
    • Terminated
    • Centrum Onkologii Ziemi Lubelskiej im. sw. Jana z Dukli, Oddzial Urologiczny
  • Poland
    • Przemyśl, Poland, Poland, 37-700
      • Recruiting
      • Wojewodzki Szpital im Sw. Ojca Pio w Przemyslu, Oddzial Urologiczny z Pododdzialem Urologii Onkologicznej
      • Contact: Rafał Walczak, MD
      • Principal Investigator: Rafał Walczak, MD
  • Warszawa
    • Warsaw, Warszawa, Poland, 02-637
      • Terminated
      • Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji im. prof. dr hab. med. Eleonory Reicher
• Spain
  • Barcelona, Spain, 08036
    • Recruiting
    • Hospital Clinic Barcelona
    • Contact: Ribal Caparros, MD
    • Principal Investigator: Ribal Caparros, MD
  • Bilbao, Spain, 48013
    • Recruiting
    • Hospital Universitario de Basurto
    • Contact: Ainara Rabade Ferreiro, MD
    • Principal Investigator: Ainara Rabade Ferreiro, MD
  • Córdoba, Spain, 14004
    • Recruiting
    • Hospital Universitario Reina Sofía
    • Contact: Garcia Rubio Jose Horacio, MD
    • Principal Investigator: Garcia Rubio Jose Horacio, MD
  • Granada, Spain, 18014
    • Recruiting
    • Hospital Universitario Virgen de las Nieves
    • Contact: Fernando Vàzquez Alonso, MD
    • Principal Investigator: Fernando Vàzquez Alonso, MD
  • Madrid, Spain, 28040
    • Recruiting
    • Hospital Fundación Jiménez Díaz
    • Contact: Juan Ignacio Monzo Gardiner, MD
    • Principal Investigator: Juan Ignacio Monzo Gardiner, MD
  • Madrid, Spain, 28041
    • Recruiting
    • Hospital Universitario 12 de Octubre
    • Contact: Ramos Guerrero, MD
    • Principal Investigator: Ramos Guerrero, MD
  • Madrid, Spain, 28050
    • Recruiting
    • Centro Integral Oncologico Clara Campal
    • Contact: Felix Guerrero Ramos, MD
    • Principal Investigator: Felix Guerrero Ramos, MD
  • Madrid, Spain, 28922
    • Terminated
    • Hospital Universitario Fundacion Alcorcon
  • Málaga, Spain, 29010
    • Recruiting
    • Hospital Universitario Virgen de la Victoria
    • Contact: Felipe Sáez Barranquero, MD
    • Principal Investigator: Felipe Sáez Barranquero, MD
  • Barcelona
    • Barcelona, Barcelona, Spain, 08035
      • Recruiting
      • Vall d'Hebron Barcelona Hospital
      • Contact: Carlos Xavier Raventós Busquets, MD
      • Principal Investigator: Carlos Xavier Raventós Busquets, MD
    • Barcelona, Barcelona, Spain, 08907
      • Recruiting
      • Hospital Universitari de Bellvitge
      • Contact: Francesc Vigues, MD
      • Principal Investigator: Francesc Vigues, MD
  • Valencia
    • Valencia, Valencia, Spain, 46009
      • Recruiting
      • Instituto Valenciano de Oncologia
      • Contact: Jose L Dominguez-Escrig, MD
      • Principal Investigator: Jose L Dominguez-Escrig, MD
• United Kingdom
  • Huddersfield, United Kingdom, HD3 3EA
    • Recruiting
    • Huddersfield Royal Infirmary
    • Contact: Tahir Qayyum, MD
    • Principal Investigator: Tahir Qayyum, MD
  • Leeds, United Kingdom, LS9 7TF
    • Recruiting
    • St James's University Hospital
    • Contact: Sanjeev Kotwal, MD
    • Principal Investigator: Sanjeev Kotwal, MD
  • London, United Kingdom, EC1A7BE
    • Recruiting
    • Barts Health NHS Trust
    • Contact: Bernadett Szabados, MD
    • Principal Investigator: Bernadett Szabados, MD
  • Plymouth, United Kingdom, PL6 8DH
    • Recruiting
    • Derriford Hospital
    • Contact: Paul Hunter-Campbell, MD
    • Principal Investigator: Paul Hunter-Campbell, MD
  • Preston, United Kingdom, PR2 9HT
    • Recruiting
    • Royal Preston Hospital
    • Contact: Michal Smolski, MD
    • Principal Investigator: Michal Smolski, MD
  • Sutton, United Kingdom, SM2 5PT
    • Recruiting
    • Royal Marsden Hospital - Surrey
    • Contact: Pardeep Kumar, MD
    • Principal Investigator: Pardeep Kumar, MD
  • Kent
    • Dartford, Kent, United Kingdom, DA2 8DA
      • Recruiting
      • Darent Valley Hospital
      • Contact: Sanjeev Madaan, MD
      • Principal Investigator: Sanjeev Madaan, MD
• United States
  • Arizona
    • Gilbert, Arizona, United States, 85234
      • Recruiting
      • Banner Health- MD Anderson Cancer Center
      • Contact: Joseph Mashni, MD
      • Principal Investigator: Joseph Mashni, MD
  • Louisiana
    • New Orleans, Louisiana, United States, 70124
      • Recruiting
      • Ochsner Clinic Foundation
      • Principal Investigator: Stephen Bardot, MD
      • Contact: Stephen Bardot, MD
  • Maryland
    • Baltimore, Maryland, United States, 21287
      • Recruiting
      • Johns Hopkins Kimmel Cancer Center
      • Principal Investigator: Max Kates, MD
      • Contact: Max Kates, MD
  • Minnesota
    • Minneapolis, Minnesota, United States, 55455
      • Recruiting
      • University of Minnesota
      • Principal Investigator: Hamed Ahmadi, MD
      • Contact: Hamed Ahmadi, MD
  • Ohio
    • Cincinnati, Ohio, United States, 45212
      • Recruiting
      • TriState Urologic Services PSC Inc. DBA The Urology Group
      • Principal Investigator: Marc Pliskin, MD
      • Contact: Marc Pliskin, MD
  • South Carolina
    • Charleston, South Carolina, United States, 29425
      • Recruiting
      • Medical University of South Carolina (MUSC)
      • Contact: Stephen J Savage, MD
      • Principal Investigator: Stephen J Savage, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Willing and able to freely provide written informed consent (in presence of an Independent Witness if applicable) prior to performing study procedures.
2. Age 18 years or older, male or female.
3. Persistent or recurrent histologically confirmed CIS of the bladder with or without concomitant recurrent HG Ta-T1 and with no evidence of metastases demonstrated by abdominal CT scan or MRI.

4. "BCG unresponsive" patients who refuse radical cystectomy or are not clinically suitable for cystectomy. BCG unresponsive disease is defined as persistent or recurrent CIS alone or with recurrent HG Ta-T1 within 12 months of completion of adequate BCG therapy.

   Adequate BCG therapy is defined as at least one of the following:

   • At least five full doses of six doses of an initial induction course plus at least two full doses of three doses of maintenance therapy.
   • At least five full doses of six doses of an initial induction course plus at least two full doses of six doses of a second induction course.

5. Complete resection of Ta-T1 papillary lesions before entering the trial in patients with concomitant CIS and papillary tumors (residual CIS acceptable, obvious areas of CIS should also be fulgurated).

   1. In patients with T1 papillary lesions undergoing resection of the base of the lesion, the biopsy should contain muscle fibers.
   2. In patients undergoing transurethal resection of their bladder tumors, absence of locally advanced disease should be confirmed by pelvic examination under anesthesia.
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2

7. Adequate organ function:

   • absolute neutrophil count ≥ 1,500/mm3,
   • platelets ≥ 100,000/mm3,
   • hemoglobin ≥ 8.5 g/dL,
   • ALT/AST ≤1. 5 x upper limit of normal (ULN),
   • alkaline phosphatase ≤ 5 x ULN,
   • total serum bilirubin ≤ 1.5 x ULN, for patients with Gilbert's ≤ 3 X ULN,
   • serum creatinine ≤ 2.2 mg/dL.

8. Women in non-reproductive years (defined as surgically sterile or one year postmenopausal). Women of childbearing potential (WOCBP) must have a negative serum pregnancy test upon entry into this study and agree to use highly effective contraceptive methods, i.e. methods that can achieve a failure rate of less than 1% per year when used consistently and correctly. Such methods include:

   • combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:

     • oral
     • intravaginal
     • transdermal

   • progestogen-only hormonal contraception associated with inhibition of ovulation:

     • oral
     • injectable
     • implantable
   • intrauterine device (IUD)
   • intrauterine hormone-releasing system (IUS)
   • bilateral tubal occlusion
   • vasectomised partner (*)
   • sexual abstinence (**)

9. Male patients with WOCBP partners must agree to use effective contraceptive methods, i.e.:

   • condom;
   • consider contraception for non-pregnant WOCBP partner.
10. Able and willing to comply with the scheduled visits, therapy plans, and laboratory tests required in this protocol.

(*) Vasectomised partner is a highly effective birth control method provided that partner is the sole sexual partner of the WOCBP trial participant and that the vasectomised partner has received medical assessment of the surgical success.

(**) Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated to the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject.

Exclusion Criteria:

1. Current or previous muscle-invasive disease (T2-T4) or metastatic urothelial carcinoma.
2. Patients with more than 12 months between inclusion and the last BCG instillation
3. Suspected hypersensitivity to paclitaxel or to any of the Oncofid-P-B constituents.
4. Previous or concomitant urothelial carcinoma of the upper urinary tract or the prostatic urethra. Freedom from upper tract disease must be demonstrated by intravenous pyelogram, retrograde pyelogram, CT scan or MRI.
5. Current or prior systemic therapy for bladder cancer.
6. Intravesical therapy within 4 weeks prior to beginning study treatment with the exception of cytotoxic agents (e.g. mitomycin C, doxorubicin and epirubicin) when administered as a single instillation immediately following a TURBT procedure between 14 to 60 days prior to beginning study treatment.
7. Symptomatic urinary tract infection or bacterial cystitis.
8. Major surgery, other than diagnostic, within 4 weeks prior to treatment.
9. Patients who have previous or concurrent malignancies that require treatment and are not clinically stable; examples of permitted concurrent recent second malignancies are: adequately treated basal cell or squamous cell skin cancer, in situ carcinoma of the cervix or prostate cancer on active surveillance at low risk for progression, defined as prostate-specific antigen (PSA) <10 ng/mL, Gleason score 6 or less and cT1.
10. Subjects who, in the opinion of the Investigator, cannot tolerate intravesical administration or intravesical surgical manipulation (cystoscopy, biopsy) due to the presence of serious comorbid condition(s) (e.g., uncontrolled cardiac or respiratory disorders).
11. Presence of significant urologic disease interfering with intravesical therapy.
12. Current enrollment or participation in another therapeutic clinical trial within 6 months preceding screening. Patients previously included in a BCG-only study arm might be enrolled following discussion with the medical monitor and/or sponsor if the definition of adequate BCG therapy is met.
13. Known substance and/or alcohol abuse.
14. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry in this study or could compromise protocol objectives.
15. Pregnancy, lactating women or women of childbearing potential (WOCBP) unwilling to use adequate birth control measures for the duration of the study and until 3 months after the end of treatment.
16. Male patients with WOCBP partners unwilling to use contraceptive methods for the duration of the study and until 6 months after the end of treatment.

17. Subjects who have a mean QTc >450 msec for males and >470 msec for females at baseline and who need concomitant medications which may cause QT prolongation.

    Applies to France Only:

18. Persons deprived of liberty by judical or administrative decision, adults subjects to a legal protection measure (under guardianship/curators), persons under protective measures and persons not affiliated with social security will be excluded from the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)	Drug: ONCOFID P-B (PACLITAXEL-HYALURONIC ACID); Schedule: once a week for 12 consecutive weeks (induction phase). Patients who achieve a complete response at the end of the induction phase will enter the maintenance phase, during which ONCOFID-P-B is administered once a month for 12 months until recurrence or progression of the disease.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Centrally assessed Complete Response Rate (CRR) at any time.	CRR calculated as the proportion of patients achieving a CR at any time within 24 months after induction or re-induction start. CRR will be based on central assessment of response	CRR will be evaluated at any time from enrollment to 24 months after induction or re-induction start.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Centrally assessed CRR	CRR calculated as the proportion of patients achieving a CR at 6, 9, 12, 15, 18, 21, 24, 30, 36, 42 and 48 months after induction or re-induction start	CRR will be evaluated at 6, 9, 12, 15, 18, 21, 24, 30, 36, 42 and 48 months after induction or re-induction
Duration of Response (DoR)	DoR defined as the time from first documented evidence of CR to time of documented recurrence (CIS or Ta-T1), progression to MIBC, to extravesical disease, or death	DoR will be evaluated at 6, 9, 12, 15, 18, 21, 24, 30, 36, 42 and 48 months after induction or re-inductiononths after treatment start
Duration of Response (DoR) rate	DoR rate calculated as the proportion of patients who maintained a CR after 6, 9, 12, 15, 18, 21, 30, 36, 42 and 48 months after induction or re-induction start.	DoR rates will be evaluated at 6, 9, 12, 15, 18, 21, 30, 36, 42 and 48 after induction or re-induction start
Progression rate	Progression rate calculated as the proportion of patients with muscle invasion or extravesical expansion of the disease at EOIT/EORIT, 15, 24 and 48 months after induction or re-induction start	Progression rate will be evaluated at EOIT/EROIT, 15, 24 and 48 months after induction or re-inductionstart
Time to progression	Time to progression defined as time from treatment start to time of documented tumor progression to MIBC or extravesical disease.	Time to progression will be evaluated at 15, 24 and 48 months after induction or re-induction start
Rate of patients undergoing cystectomy	Proportion of patients undergoing cystectomy for disease progression at EOIT/EORIT, 9, 15, 24 and 48 months after induction or re-induction start.	Rate of patients undergoing cystectomy will be evaluated at EOIT/EROIT, 9, 15, 24, 24 and 48 months after induction or re-induction start.
Time to cystectomy defined as time from start of treatment to the date of cystectomy	Time to cystectomy is defined as the time (months) form start of treatment to the date of cystectomy, analyzed using the Kaplan-Meier method. The median time to cystectomy will be presented along with 95% CI.	from start of treatment to date of cystectomy
event-free survival (EFS)	EFS defined as time from treatment start to the time of documented recurrence after CR, or progression or death due to any cause.	Event-free survival (EFS) will be evaluated at any time during the study up to 48 months after treatment start
Overall survival (OS)	OS defined as time from treatment start to death due to any cause.	overall survival (OS) will be evaluated at any time during the study up to 48 months after treatment start
Incidence of Treatment-Emergent Adverse Events (Overall Safety)	Overall safety and tolerability evaluated throughout the study on the basis of the incidence, nature, severity and causality of TEAEs, coded to preferred term and system organ class (SOC) using the Medical Dictionary for Regulatory Activities (MedDRA) and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5 and the incidence of serious adverse events (SAEs)	Safety data will be evaluated up to study month 16
Treatment time of retention (tolerability)	The tolerability of ONCOFID-P-B expressed as the ability to retain intravesical instillation for the desired dwell time (optimal retention time is 120 minutes) and measured as time of retention.	Tolerability will be evaluated up to study month 16

Collaborators and Investigators

• Sponsor: Fidia Farmaceutici s.p.a.

Study record dates

Study Major Dates

• Study Start (Actual): December 29, 2022
• Primary Completion (Estimated): May 1, 2028
• Study Completion (Estimated): December 1, 2030

Study Registration Dates

• First Submitted: August 20, 2021
• First Submitted That Met QC Criteria: August 25, 2021
• First Posted (Actual): August 27, 2021

Study Record Updates

• Last Update Posted (Actual): May 22, 2026
• Last Update Submitted That Met QC Criteria: May 19, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Male Urogenital Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Neoplasms by Histologic Type; Neoplasms, Glandular and Epithelial; Urologic Neoplasms; Urinary Bladder Diseases; Carcinoma; Carcinoma in Situ; Urinary Bladder Neoplasms; Antineoplastic Agents; Immunologic Factors; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antineoplastic Agents, Phytogenic; Protective Agents; Adjuvants, Immunologic; Viscosupplements; Paclitaxel; Hyaluronic Acid
• Other Study ID Numbers: R39_21_01

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No